You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202016709
Dec 20205207
Jan 20212804
Feb 20212308
Mar 2021148022
Apr 20213405
May 202121012
Jun 2021007
Jul 2021007
Aug 2021003
Sep 2021008
Oct 202126017
Nov 202158024
Dec 20213607
Jan 202266012
Feb 20224205
Mar 20229807
Apr 20225607
May 20228206
Jun 202266016
Jul 20229601
Aug 20223406
Sep 20225201
Oct 20225603
Nov 20226609
Dec 20222801
Jan 202336015
Feb 20234808
Mar 20235004
Apr 202382012
May 20234408
Jun 20232807
Jul 20234205
Aug 20234205
Sep 20235604
Oct 20234609
Nov 20235606
Dec 20234602
Jan 20243600
Feb 20243003
Mar 20243801
Apr 20243404
May 20243004
Jun 20245809
Jul 20245702
Aug 202446010
Sep 20244605
Oct 202464016
Nov 20245005
Dec 20244004
Jan 20252403
Feb 2025406
Mar 2025006
Apr 2025009
May 2025003
Jun 2025006
Total24680395